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We describe multifunctional magnetic nanoparticles (MNPs) encapsulated in 
thermosensitive, drug-bearing shells and delivered to the tumor site by genetically modified 
and non-pathogenic strains of bacteria with known affinity to tumors for an effective and 
minimally invasive protocol for tumor management.  The magnetic nanoparticles also serve 
as a non-invasive imaging contrast agent, heating agent as well as thermometry monitoring 
agents.  We have shown an efficient tumor management on a mouse model utilizing the 
MNPs. Our studies showed that these novel MNPs significantly reduce the progress of tumor 
and prolong the animal life and function as an imaging contrast to visually monitor the tumor 
treatment and evolution.  
 
An ideal therapeutic approach is to target multiple facets of the cancerous process 
while sparing the normal cells; a cocktail of drugs may achieve this goal if it can be delivered 
to specific tumor target to achieve optimal drug levels in the tumor without increase it’s 
systemic side effects. However, multiplexing the diagnosis, targeted delivery, and monitoring 
remains a major technical challenge for cancer research. 
Hyperthermia is a known modality of cancer therapy based on the vulnerability of the 
tumor cells to high temperatures.  The viability of the cancerous cells is reduced and their 
sensitivity to chemotherapy and radiation is increased by raising the temperature of the target 
tissue to 42- 46°C1-5. Cancer cells have high potential to be destroyed at about 43°C while 
normal cells can survive higher temperatures of 46°C. Various methods of applying 
hyperthermia has been tried, such as the use of hot water, capacitive heating, and inductive 
heating of malignant cells6-9. The possibility of treating cancer by artificially induced 
hyperthermia has lead to the development of many different devices designed to heat 
malignant cells while sparing surrounding healthy tissue10-12.  
A number of studies have demonstrated the therapeutic efficacy of hyperthermia form 
of treatment in animal models5 but the application of this technology to human patients is just 
starting13. Experimental investigations of the application of magnetic materials for 
hyperthermia date back to 1957 when Gilchrist14, heated various tissue samples using γ -
Fe2O3 particles of 20-100 nm size exposed to a 1.2 MHz magnetic field. Since then, there 
have been numerous publications describing a variety of schemes using different types of 
magnetic materials, different field strengths and frequencies and different methods of 
encapsulation and delivery of the particles15-24. In broad terms, the procedure involves 
dispersing magnetic particles throughout the target tissue, and then applying an AC magnetic 
field of appropriate strength and frequency to cause the particles to heat. This heat conducts 
into the immediately surrounding diseased tissue where cancerous cells are destroyed if the 
temperature can be maintained above the therapeutic threshold of 42°C for at least 30 min. 
Whereas the majority of hyperthermia devices are restricted in their utility because of 
unacceptable coincidental heating of the surrounding normal tissue, magnetic particle 
hyperthermia is appealing because it offers a way to ensure that only the intended target 
tissue is heated. The concept is based on the principle that a magnetic particle can generate 
heat by hysteresis loss (other forms of heat dissipation based on particle size and composition 
may apply) when placed in a high frequency ~1 MHz magnetic field25. It has been shown 
that malignant cells take up nine times more MNPs than normal cells26. Therefore the heat 
generated in malignant cells is more than that in normal cells. Also, as blood supply in the 
cancerous tissues is subnormal the heat dissipation is much slower. Hence, the temperature 
rise in the region of tumor is higher than in the surrounding normal tissues. It is therefore 
expected to have a stronger antitumoral effect in areas with more concentrated heat.  
The latest magnetic hyperthermia modalities are based on micro- and nano-scale 
mediators in the form of an injectable colloidal dispersion of magnetic particles and may be 
performed according to three strategies: arterial immobilization hyperthermia - AEH, direct 
injection hyperthermia - DIH, and intracellular hyperthermia - IH27.  All these three 
approaches lack the capacity to assess the loading and distribution of particles at the tumor 
site, continuous monitoring of the immobilization, and treatment progress.  We report a novel 
procedure that provides image-guided hyperthermia for tumor treatment; this procedure uses 
novel classes of multifunctional magnetic nanoparticles and has been shown to be safe, 
durable, and have excellent heating ability.   
Image-guided therapies provide a unique multimodal approach to overcome the 
challenges associated with non-invasive monitoring of the therapy. Nanotechnology may 
offer solutions in overcoming these challenges by providing smart materials with 
multifunctional abilities that are created by controlling their physical properties during the 
synthesis process. Magnetic particles have been used as contrast agents, therapeutic agents 
and drug delivery agents28-31.   
Procedures such as hyperthermia therapy, cardiac arrhythmias treatment and heat 
sensitive promoters in gene therapy require temperature change monitoring.  MRI 
thermometry overcomes problems associated with invasive temperature monitoring 
techniques such as thermocouples and fiber optics.  In the current MRI thermometry the 
temperature variation is detected by measuring small changes in the proton resonant 
frequency32, longitudinal relaxation time33 or apparent diffusion coefficient34.  However, 
these techniques have low temperature sensitivity and influenced by the local motion and 
magnetic susceptibility variation35.  Liposome-encapsulated gadolinium chelates that have 
phase change characteristic were reported36.  The temperature during the phase transition can 
be indicative of the local tissue temperature.  However, this technique provides a one value 
for the temperature not a map of temperature distribution and requires careful design for the 
carrier.  
Material with detectable physical property at different temperatures provides a 
suitable alternative for thermo-mapping at different locations.  Coupling, the temperature 
dependence with a physical quantity that can be measured non-invasively provides a unique 
technique for temperature mapping in deep-seated tissue.  Our MNPs have magnetic moment 
temperature dependence that can provide the desired multifunctional actions.  They have a 
contrast ability signature, temperature signature, and can be utilized as agents for 
hyperthermia therapy. The difference in magnetic moment size between the tissue and the 
MNPs causes additional contrast in magnetic resonance imaging. MNPs with steep variation 
in their magnetic moment as a function of temperature elevation provide information about 
the tissue temperature. 
We synthesized multifunctional nanoparticles in the form of ZnGdxFe(2-x)O4.  Various 
samples of Gd-substituted Zn Ferrite nanoparticles were synthesized using chemical co-
precipitation method in which the metal salts (e.g., FeCl3, Fe2SO4, ZnSO4, GdCl3) were 
added to an NaOH solution. After vigorous stirring and filtration, newly synthesized particles 
were washed and then allowed to air dry at room temperature37. 
When comparing the characterization data of the Gd-substituted Zn Ferrite particles 
with that of the Zn-Ferrite particles it was noticed that addition of Gd in small amounts lead 
to an increase in the Curie temperature (Tc) as well as the pyromagnetic co-efficient of the 
nanoparticles. Figure 1-a shows the magnetic moment of particles as a function of 
temperature for x=0.02, and Figure 1-b shows the variation of their Tc as a function of x.  
The XRD pattern is shown in Figure 2.  The pattern confirms the formation of single-phase 
spinel structure.  TEM micrograph of the dispersion of ZnGd-ferrite nanoparticles in ethanol 
deposited over a Cu grid are shown in Figure 3. The sample consists of a dispersion of almost 
spherical particles with a narrow size distribution.  The histogram of the diameter from a 
statistical analysis over 100 particles is shown in the insert.  The distribution fits a Gaussian 
distribution with mean±sd diameter of 5.5 ± 0.9 nm.  The obtained value is closed to that 
obtained from XRD measurement indicating a high crystalline degree of all particles38.  The 
nanoparticles systems developed generate sufficient heat (specific absorption rate SAR 
[W/g]) and stop heating at the measured Tc. The power dissipated from the nanoparticles 
systems was calculated from the area enclosed by the hysteresis loop. These chemically 
synthesized nanoparticles were tested for cyto-toxicity by MTT assay, on normal human and 
cancerous cell lines. No significant toxicity was found. No signs of toxicity were observed on 
25 BalB/c mice according to http://ctep.info.nih.gov protocols.    
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Figure 1-a. Temperature dependance of 
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We further investigated the use of these MNPs, as new MRI contrast agents. We 
hypothesized that if relaxation rates are shown to be temperature-sensitive it is anticipated 
that these agents would then be used as thermometry agents and hence improve the efficacy 
of many clinical procedures, e.g. hyperthermia treatment.  
We have investigated the MR longitudinal (T1) and transverse (T2) relaxation enhancement 
due to different concentrations of the Zn-Gd-Fe family of uncoated MNPs. A fast spin-echo 
(FSE) imaging sequence has been used at a field strength of 1.5 T with the following 
parameters: for the T1 measurement an inversion recovery sequence is used with TI = 50, 
100, 300, 700, 1200, 2000, and 3000 ms; with a TE = 15 ms; while for the T2 measurement a 
spin-echo sequence with TE = 15, 30, 45, 60, 100, and 150 ms. Particles were prepared in 
viscous cellulose solutions to maintain them in suspension.  The concentrations were  C = 
0.29, 0.57, 1.14, 2.28, and 03.40 mmol/kg weight in addition to the control (i.e. C = 0.0). 
Signal intensity is plotted versus TE for various concentrations (Figure 4) at 23 oC.  Single 
exponential curve was fitted to the data using non-linear programming (Levenberg-
Marquardt) minimizing an error function to yield the time constant T2.  R2 enhancement is 
linear with C as shown in Figure 5. The relaxivity (r2) as defined by the equation (R2(C) = 
R20 + r2 C) is 240 (s mmol/kg)-1. R20 is the transverse relaxation rate in the absence of MNPs. 
Similar analysis for the T1 data revealed r1 = 1.8 (s mmol/kg)-1. 
Figure2. X-ray diffraction pattern Figure 3 . TEM and particle size 
distribution  
    
Figure 4. FSE signal variation with echo-time Figure 5. Transverse relaxation rate vs. 
concentration at temperature = 23oC. 
 
Spin-echo T2 weighted for different values of the echo time (TE).  Signal decay variation 
with both concentration (different tubes) and TE is clearly demonstrated.  The calculated 
values for the relaxation rates R1 and R2 are shown in Table 1 along with their ratio R2/R1 at 
23 oC. As expected for superparamagnetic particles R2 >> R1. The effect of MNPs will be to 
produce negative image contrast (i.e. signal reduction due to T2 wieghting is more 
pronounced than signal elevation due to T1 weighting).  
Table 1: R1 and R2 values at different concentrations of the nanoparticles at 23 oC. 
C (mmol/kg) R1 (s-1) R2 (s-1) R2/R1
C 0.0 0.64 11.7 18.3 
C 0.025 0.68 20.4 29.9 
C 0.050 0.72 25.8 36.0 
C 0.100 0.82 43.1 52.4 
C 0.200 0.98 65.9 67.1 
C 0.300 1.11 90.0 81.5 
 
Upon heating the samples to temperatures blow and above the particles Curie 
temperature (42.8oC) the R1 and R2 are measured for the different concentrations. 
Normalized values of R1 and R2 are plotted in Figure 6 and 7 respectively where it is shown 
that both relaxation rates increase lineraly with both concentration of the MNPs and 
temperature. 
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Figure 6 The linear variation of 1/T1 (normalized) 
with temperature increases with the concentration 
of MNPs. 
Figure 7. As for 1/T1 the variation of 1/T2 
(normalized) is linear with temperature, 
however, the slopes are larger.  
The relaxivity (r2) values (in kg s-1 mmol-1) are summarized in Table 2.  Relaxivity 
increases linearly with temperature and data has a positive slope 0.173 and R-squared value 
0.92.  
Table 2: r2 values at different temperatures 
 
 
 
 
 
 
 
MR relaxation enhancement is demonstrated with new class of magnetic 
nanoparticles that have already been used for hyperthermia applications. The contrast ability 
(in particular R2) is found to vary linearly and significantly with concentration. Furthermore, 
the relaxation enhancement of these new contrast agents exhibits linear variation with 
temperature. This would allow the use of these MNPs particles, in addition to their role as 
contrast agents, in temperature monitoring and hyperthermia applications. 
The use of non-pathogenic bacteria in cancer therapy is an innovative approach that 
stemmed from the observation that some bacteria have tropism for tumors where they 
replicate and accumulate reaching concentrations exceeding 1000-fold their concentration in 
other target organs. It has been also shown that attenuated Salmonella typhimurium strains 
accumulate at tumor sites when injected in tumor-bearing mice while rapidly clearing from 
T (oC) 
r1 
(kg s-1 mmol-1) 
T (oC) r2(kg s-1 mmol-1) 
23.0 0.140 23.0 22.8 
34.4 0.186 38.2 27.1 
43.0 0.197 47.4 27.6 
48.9 0.212 56.6 28.8 
the blood of normal mice39-44.  Because of their selectivity for tumor tissue, these bacteria 
would make ideal carriers for contrast agents.  The use of attenuated bacteria strains as 
carriers for gene vectors45, vaccines46 and chemotherapeutic agents47 has been reported.  
However, there is limited information on the ability of loading bacteria with MNPs. 
We used bacterial delivery system to convey the NMPs alone or together with other 
cancer drugs to the tumor site. Experiments were conducted to evaluate the upload of MNPs 
into the bacteria membrane.  Salmonella BR 509 was used.  These bacteria are rod shaped 
with 1 micron in length.  Ultrafine particles were incubated with Salmonella.  Figure 8 shows 
SEM micrographs of the MNP-bacteria.  It was observed that small size particles were 
diffused into the cell membrane.  We were able to separate the MNP-bacteria from the 
sample using a permanent magnet.   
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We demonstrated the intake of MNP in a strain of attenuated Salmonella typhimurium 
BRD509. The targeting of drug-coated MNP-loaded Salmonella organisms to tumor sites 
have a great advantage over systemic administration of the anti-cancer drug as it would 
significantly reduce the toxicity associated with prolonged treatment with high doses of 
chemotherapeutic drugs. In here we encapsulated the MNPs along with anti-tumor drug (5FU 
or doxirobucine) in a thermosensitive shell. Salmonella organisms carried the coated shells to 
tumor tissue. Under the influence of a magnetic field at 0.963MHz, the tumor-targeted MNP 
generate heat up to 42° to 43°C, thus releasing the drug specifically at the tumor site. This 
way, non-specific exposure of the host to the chemotherapeutic agent is avoided.  
Figure 8 (a) SEM of encapsulated MNPs attached on the cell membrane of Salmonella, 
(b) shows that smaller NMPs entered the Salmonella’s membrane and (c) shows vertically 
aligned Salmonella when exposed to a magnetic field placed on top of the slides.  
The conditions for uptake of MNPs by live Salmonella bacteria were optimized. In 
these experiments, 1 x 108 colony forming units (CFUs) of Salmonella strain BRD509 were 
incubated with MNPs in saline buffer. At the end of the incubation period, the bacterial 
suspension was spun down and the supernatant was aspirated. After resuspending the 
bacterial pellet in 1 ml saline, the bacterial suspension was subjected to a 0.45 Tesla 
permanent magnet for 15 minutes on the outside surface of the eppendorf tube. The 
remaining supernatant, presumably containing non-MNP-associated bacteria, was aspirated, 
and replaced with fresh saline. This procedure was repeated 3 times in total. Aliquots were 
removed from the bacterial suspension before and after each wash cycle and plated to 
determine the actual count of bacterial CFUs. Using this procedure, the number of bacterial 
CFUs remaining after four cycles of magnetic separation and washing (which most likely 
represents the number of bacteria actually associated with MNPs) was determined, and hence 
the % of bacteria associated with MNPs was calculated. Figure 8 illustrates the loss of non-
MNP-associated Salmonella organisms, following co-incubation with MNPs at 24ºC for 120 
minutes, after each cycle of wash. It demonstrates that all bacteria not associated with 
nanoparticles are effectively removed by the 3rd wash cycle. Furthermore, varying the 
incubation conditions have a clear impact on the uptake of MNPs by the bacteria. Incubation 
of MNPs with live Salmonella organisms at room temperature resulted in the most optimal 
uptake, which was about 6% (6x106, sufficient for the loading purpose). The fact that the 
association appears to be strong suggests that it is feasible to use the MNP-loaded, or MNP-
associated, Salmonella organisms in tumor targeting in vivo.   
 
B6 mice (20g ± 3g) were housed in appropriate isolated caging with sterile rodent 
laboratory chow and acidified water ad libitum and a 12-h light/dark cycle.  B6 mice were 
implanted subcutaneous in the mid of tail by 50 micro liter volume of PBS with approx. 
300,000 melanoma cells, 99% viability. Tumor was visible after 20 days, 1-2mm diameter.  
Four groups of five each were prepared such that one group with no treatment (control), 
second group with drug therapy (5FU) only, third group with hyperthermia only and the 
fourth group with integrated particle that has the drug and heating agent encapsulated in the 
thermosensitive polymer.  The treatment started after a month from inoculation of the cells.  
In this experiment control group was given saline, hyperthermia (nanoparticles alone) group 
received nanoparticles in a concentration of 20mg/kg of body weight and followed by 
hyperthermia at 0.963MHz for 45 minutes. Six doses were given after every two days gap. 
Tumor volume was measured every two days until survival of mice. Tumor volume 
corresponds to width² X length / 2. Tumor temperature rises till 42-43ºC, and was monitored 
during the experiment.  Figure 9 shows the temperature distribution immediately following 
non-invasive magnetic heating of shells carrying drug load and MNPs and injected ip into the 
tail of the treated mouse.   
Close up pictures were taken for tumor to present significant difference. It was 
noticed that blood flow to tumor was increased due to increase in temperature.  The survival 
measurements showed that hyperthermia treated mice with encapsulated drug have survived 
the longest (5 times more than drug alone treated mice) a subsequent measurement of 
controlled tumor growth.   
 
  
 
 
 
 
 
 
 
Figure 9 Temperature map of heated tumor containing MNPs.  The inner pictures 
show the tumor just before introducing the treatment.   
Figure 10 shows the measured tumor volume as a function of time for all groups post 
treatment.  It is clearly shown that the multifunctional therapy has better efficacy than each of 
the therapies if they administered alone.  Figure 11 shows the survival curve for all groups.  
It is clear that the volume of the tumor has reduced dramatically and the animals survived the 
most when the hyperthermia therapy was implemented.  
 
 Figure 10. Tumor volumes for all groups.  The tumor volume is normalized with the 
control starting the first day of treatment. Day 0 is day when treatment started and the 
30th day after the inoculations of the tumor  
 Figure 11.  Survival of the animals of all groups.  
We have also tested the ability of bacteria to deliver the load of drugs without 
having to heat the tumor.  Figures 12 and 13 demonstrates that when hyperthermia 
is utilized the effectiveness of delivery and treatment are more when hyperthermia 
is utilized.  
Figure 12. Tumor volume post treatment of control, bacterial loaded with MNPs (no drug) 
and bacteria loaded with shelled drug and MNP.  Bacterial delivery is effective.  The 
mechanism of drug unloading is not fully understood, but may be associated with the bacteria 
cellular division at the tumor. 
  
 
  
In conclusion we demonstrated the functionalization of a potential imaging guided 
intervention that employs multifunctional magnetic nanoparticles with potential to provide 
targeted drug delivery and non-invasive monitoring of drug localization and thermometry.  A 
smart drug carrier with high affinity to tumors is utilized to site-specific delivery of 
thermosensitive shells bearing anticancer drug and nanoparticles.  Non-invasive localized 
heating is induced by a remote alternating magnetic field.  The intervention when applied to 
induced tumors showed preferred therapeutic management of the tumor.  
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